Pulmonary Sarcoidosis Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Pulmonary Sarcoidosis remains an active clinical development field. The landscape is diversifying across prevention, early treatment and high-risk populations, making variant coverage, resistance, seasonality and practical delivery central to differentiation. The PatSnap evidence set used here contains 44 matched trial records and 34 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| ChiCTR2600128024 | Intervention not normalized | Not Applicable; Not yet recruiting | The First People's Hospital of Hangzhou | China | Pathology results | 2027-12-31 |
| NCT07680166 | XTMAB-16 | Phase 1/2; Not yet recruiting | Xentria, Inc. | Geography not listed | Absolute change from baseline in forced vital capacity (FVC) milliliter (mL) (Baseline to Week 24) | 2029-10-31 |
| NCT07668895 | Betamethasone Dipropionate/Betamethasone Sodium Phosphate | Phase 2/3; Not yet recruiting | Peking Union Medical College Hospital | China | Change from baseline in percent predicted FVC after 24 weeks of treatment (%) (24 weeks) | 2027-07-01 |
| NCT07613216 | Intervention not normalized | Not Applicable; Not yet recruiting | Sponsor not listed | United States | 6 minute walk test (9 months) | 2027-07-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- aTyr's steroid-sparing lung disease drug disappoints in late-stage trial (Phase 3): the indexed record reports OCS Dose(week 48) = patients receiving efzofitimod managed to taper their steroid use to an average of 2.79 mg per day, compared to 3.52 mg per day in the placebo group. This reduction did not reach statistical significance, nor did it meet expert expectations; analysts had estimated that a difference of at least 2.5 mg daily would be required for a meaningful result. mg Not Met; OCS Dose(week 48) = patients receiving efzofitimod managed to taper their steroid use to an average of 2.79 mg per day, compared to 3.52 mg per day in the placebo group. This reduction did not reach statistical significance, nor did it meet expert expectations; analysts had estimated that a difference of at least 2.5 mg daily would be required for a meaningful result. mg Not Met; OCS Dose(week 48) = patients receiving efzofitimod managed to taper their steroid use to an average of 2.79 mg per day, compared to 3.52 mg per day in the placebo group. This reduction did not reach statistical significance, nor did it meet expert expectations; analysts had estimated that a difference of at least 2.5 mg daily would be required for a meaningful result. mg Not Met.
- A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis (Phase 2): the indexed record reports Percentage of Participants With a Rescue Event During the DB Period = 23.5 percentage of participants (90% Confidence Interval, 15.2 - 34.5); Percentage of Participants With a Rescue Event During the DB Period: Stratified Common Risk Difference = 14.1(90% CI, -1.0 to 29.2), P-Value = 0.1244; Percentage of Participants With a Rescue Event During the DB Period: Stratified Common Risk Difference = 14.1(90% CI, -1.0 to 29.2), P-Value = 0.1244.
- First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate (Phase 4): the indexed record reports FVC = 6.11 percentage points ( 3.72 - 8.50); FVC = 6.75 percentage points ( 4.50 - 8.99).
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including XTMAB-16 (Phase 2; TNF-α), Betamethasone Dipropionate/Betamethasone Sodium Phosphate (Approved; GR). Company & Deal Intelligence records identify sponsor context for The First People's Hospital of Hangzhou, Xentria, Inc., Peking Union Medical College Hospital. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Clinically meaningful endpoints paired with virologic or microbiologic measures.
- Evidence in immunocompromised, pediatric, pregnant and older populations.
- Resistance surveillance and combination strategies for prolonged infection.
- Coadministration, real-world effectiveness and implementation studies.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Pulmonary Sarcoidosis has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
